Furthermore, juxtacrine interaction by ubiquitin-specific peptidase 51/programmed death ligand one/integrin beta-1 has been demonstrated by Li et al. in NSCLC to the malignant tumor progression and therapeutic resistance in NSCLC (Li et al., 2023). This evidence concerns the gene ITGB1 and cancer.